187 related articles for article (PubMed ID: 30259696)
41. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
43. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
44. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
[TBL] [Abstract][Full Text] [Related]
45. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
46. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
47. Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Nie K; Zhang Z; Zhang C; Geng C; Zhang L; Xu X; Liu S; Wang S; Zhuang X; Lan K; Ji Y
Lung Cancer; 2018 Jul; 121():5-11. PubMed ID: 29858027
[TBL] [Abstract][Full Text] [Related]
48. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Ann Oncol; 2015 Sep; 26(9):1877-1883. PubMed ID: 26141208
[TBL] [Abstract][Full Text] [Related]
49. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
[TBL] [Abstract][Full Text] [Related]
51. Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.
Tan PS; Bilger M; de Lima Lopes G; Acharyya S; Haaland B
Cancer Med; 2017 Aug; 6(8):1847-1860. PubMed ID: 28675660
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
54. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Jul; 9(7):805-813. PubMed ID: 29768721
[TBL] [Abstract][Full Text] [Related]
55. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
[TBL] [Abstract][Full Text] [Related]
56. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
57. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
58. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
Sandler A; Yi J; Dahlberg S; Kolb MM; Wang L; Hambleton J; Schiller J; Johnson DH
J Thorac Oncol; 2010 Sep; 5(9):1416-23. PubMed ID: 20686429
[TBL] [Abstract][Full Text] [Related]
59. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
[TBL] [Abstract][Full Text] [Related]
60. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
